References
- Christiansen J. S., Svendsen P. A., Mathiesen E. M., Rubin R., Deckert T. Comparison of 24-hour insulin requirements in IDDM patients during control by an artificial betacell and during conventional therapy. Horm. Metab. Res. 1981, In press
- Clemens A. H. Control algorithms for artificial betacell. Horm. Metab. Res. 1979; 8: 35, suppl.
- Clemens A. H., Chang P. H., Myers R. W. The development of Biostator. a elucose controlled insulin infusion system (GCIIS). Horm. Metab. Res. 1977; 7: 23, suppl.
- Fogt E. J., Dodd L. M., Jenning E. M., Clemens A. H. Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system (Biostator®). Clin. Chem 1978; 24: 1366
- Hjelm M. Enzymatic determination of glucose in blood and urine. Scand. J. clin. Lab. Invest. 1966; 18(92)85, suppl.
- Mancini G., Carbonara A. O., Heremanns J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 1965; 2: 235
- Pfeiffer E. F., Thum C., Clemens A. H. The artificial betacell—a continuous control of blood sugar by external regulation of insulin infusion. Horm. Metab. Res 1974; 487: 339
- Pfeiffer E. F., Kerner W. The artificial endocrine pancreas: Its impact on the patholophysiology and treatment of diabetes mellitus. Diabetes Care 1981; 4: 11
- Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann. din. Biochem 1969; 6: 24